The U.S. Food and Drug Administration (FDA) has provided written feedback supporting Hepion Pharmaceuticals’ proposed clinical development plan for GV104, a new investigational treatment for gambling disorder. This marks a significant regulatory step as there are currently no FDA-approved medications for this psychiatric condition. Hepion, through its subsidiary Gravitas Life Sciences, aims to file an Investigational New Drug (IND) application and begin Phase 2 trials in 2027.
FDA Guidance and Next Steps
The FDA’s Division of Psychiatry responded to Hepion’s pre-IND meeting request, offering guidance on the regulatory pathway, nonclinical requirements, and the design of the planned Phase 2 study for GV104. The agency indicated that Hepion can reference existing nonclinical and manufacturing data from a prior program, potentially streamlining the process. The FDA also found the proposed 12-week proof-of-concept study design and its primary endpoint assessment tool to be generally appropriate.
About GV104 and Gambling Disorder
GV104 is a transmucosal buccal film containing nalmefene, an opioid receptor modulator already approved in the U.S. for opioid overdose in injectable and nasal spray forms. For gambling disorder, nalmefene and similar compounds have been studied for years, but none have received regulatory approval. Gambling disorder is classified as a non-substance-related addictive disorder, with treatment currently limited to counseling and psychosocial interventions. Hepion intends for GV104 to be used alongside these established therapies, not as a replacement.
Implications for the Gambling Sector
The FDA’s support for advancing GV104 into clinical trials could be a turning point for the treatment of gambling disorder. For operators and affiliates, this development highlights a growing recognition of gambling-related harms and the potential for medical treatment options. Should GV104 or similar drugs eventually receive approval, operators may face new expectations around responsible gambling protocols and player support. Regulators could also see increased pressure to update guidelines and collaborate with healthcare providers as new treatment options emerge.
Key takeaways
- The FDA has supported Hepion’s plan for Phase 2 trials of GV104 for gambling disorder.
- GV104 is based on nalmefene, an opioid receptor modulator not yet approved for this use.
- No FDA-approved drugs currently exist for gambling disorder; care relies on psychosocial support.
- This regulatory step could eventually impact responsible gambling policies for operators and affiliates.